Skip to main content

ENGLISH · EVIDENCE OVERVIEW

hGH Fragment 176-191
evidence profile

Growth-hormone C-terminal peptide fragment. This is a concise English overview, not a full translation. Read the evidence boundaries and original sources below; the detailed study and risk discussion remains available in Thai.

What do Class, Grade and Risk mean?

hGH Fragment 176-191: conceptual scientific illustration for Growth Hormone Biology
VISUAL GUIDE · hGH Fragment 176-191

Growth Hormone Biology

Category-level conceptual illustration, not a map of this molecule's receptor targets. It is not a treatment outcome and does not establish efficacy or safety.

QUICK ANSWER · AEO / GEO

hGH Fragment 176-191 is not full-length somatropin and should not be equated with AOD-9604 without structural verification. A rat study reported glucose/insulin effects of several C-terminal fragments. It does not establish human fat loss or freedom from metabolic risk.

01

ENTITY FACTS

What should readers identify first?

MOLECULEhGH Fragment 176-191
PHARMACOLOGYGrowth-hormone C-terminal peptide fragment
PRIMECORE CLASSC
EVIDENCE GRADEE
RESEARCH TOPICGrowth Hormone Biology
LAST REVIEWED2026-08-30

What remains unknown?

Insufficient data in the current dataset

What limits these conclusions?

English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty.

Read original excerpts (Thai / mixed language)
  • Fragment identity ≠ AOD-9604 trial formulation ≠ somatropin approval; ไม่รับรองการลดไขมันเฉพาะจุด

This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.

02

EVIDENCE BOUNDARY

What this overview does not establish

  • An evidence grade does not rank this molecule against another treatment.
  • A molecule name does not establish the identity, purity or regulatory status of a product.
  • Animal, cell or biomarker findings do not automatically establish human clinical benefit.
  • Approval in one country or indication does not transfer globally.

Where can I check the evidence?

Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.

  1. C-terminal-fragment experiment · PMID 645904
03

FAQ · ANSWER ENGINE

Frequently asked questions

What is hGH Fragment 176-191?

hGH Fragment 176-191 is described pharmacologically as Growth-hormone C-terminal peptide fragment. hGH Fragment 176-191 is not full-length somatropin and should not be equated with AOD-9604 without structural verification. A rat study reported glucose/insulin effects of several C-terminal fragments. It does not establish human fat loss or freedom from metabolic risk.

Does hGH Fragment 176-191 have strong evidence?

PrimeCoreBio records Evidence Grade E. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.

Is hGH Fragment 176-191 approved everywhere?

No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.

Medical Disclaimer

Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.

Contact PrimeCoreBio

Choose a contact channel

General information only · No sales or medical advice